These Form 3 filings confirm insider ownership ahead of a potential IPO. Monitor for an S-1 registration statement or IPO pricing announcement, which would trigger conversion of preferred shares and provide the first public market valuation.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 13 $28.50entry
- T+1 · 15h ago +5.40%α +7.32% · $30.04
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Four insiders filed initial statements of beneficial ownership (Form 3) for Windward Bio Group AG, a pre-IPO biotech. CEO Luca Santarelli holds 4,578,110 common shares directly; CMO Omar Khwaja holds 642,136 common shares directly; director David P. Bonita (OrbiMed) reports indirect ownership of 531,632 common shares, 3,561,936 common shares via Series A preferred conversion, 1,611,008 common shares via Series B preferred conversion, and 216,668 warrants; director Otello Stampacchia (Omega Funds) reports indirect ownership of 1,262,628 common shares via Omega VII, 1,262,626 common shares via Omega VIII, 531,632 common shares via Omega VII Series B, and 531,634 common shares via Omega VIII Series B. The filings are routine Section 16 compliance for a company that appears to be preparing for an IPO, as indicated by the automatic conversion of preferred shares immediately prior to the IPO closing.
Key Facts
- CEO Luca Santarelli holds 4,578,110 common shares directly and 163,854 employee share options exercisable at $0.02
- CMO Omar Khwaja holds 642,136 common shares directly and 318,830 employee share options exercisable at $0.02
- Director David P. Bonita (OrbiMed) reports indirect beneficial ownership of 531,632 common shares, 3,561,936 common shares via Series A preferred, 1,611,008 common shares via Series B preferred, and 216,668 warrants exercisable at $0.02
- Director Otello Stampacchia (Omega Funds) reports indirect beneficial ownership of 1,262,628 common shares via Omega VII, 1,262,626 common shares via Omega VIII, 531,632 common shares via Omega VII Series B, and 531,634 common shares via Omega VIII Series B
- Series A and Series B preferred shares automatically convert to common shares on a 1:1 basis immediately prior to the closing of the issuer's initial public offering
- The warrants and employee options are fully vested or vesting in monthly installments, with exercise prices reflecting CHF to USD conversion rates
Financial Impact
No financial impact; routine initial ownership disclosures for a pre-IPO company
Risk Factors
- No revenue or financial data disclosed; company is pre-revenue biotech with no approved products
- IPO may not occur or may be delayed, leaving preferred shares unconverted and insiders locked in
Documents Analyzed
This report is based on 16 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (WWB), Batch item 1 | 0001572451-26-000008 |
| Document: 0001572451-26-000008-index-headers.html | 0002162137-26-000003 |
| Document: 0001572451-26-000008-index.html | 0001776393-26-000005 |
| Document: 0001572451-26-000008.txt | 0001361712-26-000007 |
| 3 Filing (WWB), Batch item 5 | 0002162137-26-000003 |
| Document: 0002162137-26-000003-index-headers.html | 0001572451-26-000008 |
| Document: 0002162137-26-000003-index.html | 0001572451-26-000008 |
| Document: 0002162137-26-000003.txt | 0001572451-26-000008 |
| 3 Filing (WWB), Batch item 9 | 0001776393-26-000005 |
| Document: 0001776393-26-000005-index-headers.html | 0001572451-26-000008 |
| Document: 0001776393-26-000005-index.html | 0001572451-26-000008 |
| Document: 0001776393-26-000005.txt | 0001572451-26-000008 |
| 3 Filing (WWB), Batch item 13 | 0001361712-26-000007 |
| Document: 0001361712-26-000007-index-headers.html | 0001572451-26-000008 |
| Document: 0001361712-26-000007-index.html | 0001572451-26-000008 |
| Document: 0001361712-26-000007.txt | 0001572451-26-000008 |
Track record
15 reports on WWB
Filters
- Nov 16, 2026today Press Release Neutral 5/10 Entry $30.04 Now $30.04 +0.00% settles Dec 16
- Nov 13, 20263d ago Press Release Bullish 5/10 Entry $18.35 Now $30.04 +63.71% settles Dec 15
- Nov 13, 20263d ago EFFECT Neutral 6/10 Entry $28.50 Now $30.04 +5.40% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $28.50 Now $30.04 +5.40% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 1/10 Entry $28.50 Now $30.04 +5.40% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Viewing Entry $28.50 Now $30.04 +5.40% settles Dec 14
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $28.50 Now $30.04 +5.40% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 3/10 Entry $28.50 Now $30.04 +5.40% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $28.50 Now $30.04 +5.40% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $28.50 Now $30.04 +5.40% settles Dec 14
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers